News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EpiCept Corporation (EPCT) Provides Update on Ceplene® Manufacturing at Ben Venue Laboratories



12/21/2011 6:23:39 AM

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News:

EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today provided an update on the impact of the quality assurance review by the European Medicines Agency (EMA) of Ben Venue Laboratories on the availability of Ceplene® (histamine dihydrochloride).

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES